Senti Biosciences Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
SNTI$0.14-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
| September 30, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Cash and cash equivalents | $10,479 | $35,926 |
| Accounts receivable | 74 | 112 |
| GeneFab receivable - related party | 1,113 | 17,592 |
| GeneFab prepaid expenses - related party | 3,872 | 14,787 |
| Prepaid expenses and other current assets | 1,846 | 2,783 |
| Total current assets | 17,384 | 71,200 |
| Restricted cash | 3,561 | 3,522 |
| GeneFab receivable - related party, net of current portion | — | 1,119 |
| Property and equipment, net | 22,218 | 25,338 |
| Operating lease right-of-use assets | 14,470 | 16,274 |
| GeneFab Economic Share - related party | — | 1,816 |
| Other long-term assets | 88 | 215 |
| Total assets | $57,721 | $119,484 |
| Liabilities and Stockholders’ Equity | ||
| Accounts payable | $793 | $1,250 |
| Finance lease liabilities - related party, current portion | 103 | 97 |
| Early exercise liability, current portion | 45 | 135 |
| GeneFab sublease deferred income - related party | 639 | 989 |
| Accrued expenses and other current liabilities | 2,978 | 5,927 |
| Operating lease liabilities | 4,486 | 4,031 |
| Contingent earnout liability | 20 | — |
| Current liabilities of discontinued operations | — | 243 |
| Total current liabilities | 9,064 | 12,672 |
| Operating lease liabilities, net of current portion | 30,120 | 33,538 |
| GeneFab Option - related party | — | 6,331 |
| Other liabilities, net of current portion | 2,543 | — |
| Contingent earnout liability, net of current portion | — | 20 |
| Early exercise liability, net of current portion | — | 10 |
| Total liabilities | 41,727 | 52,571 |
| Commitments and contingencies (Note 13) | ||
| September 30, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized at September 30, 2024 and December 31, 2023; zero shares issued and outstanding at September 30, 2024 and December 31, 2023 | — | — |
| Common stock, $0.0001 par value; 500,000,000 shares authorized at September 30, 2024 and December 31, 2023; 4,586,957 and 4,569,900 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | 1 | 1 |
| Additional paid-in capital | 312,517 | 311,256 |
| Accumulated deficit | (296,524) | (244,344) |
| Total stockholders’ equity | 15,994 | 66,913 |
| Total liabilities and stockholders’ equity | $57,721 | $119,484 |
All periods presented have been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on July 17, 2024. Refer to Note 2. Summary of Significant Accounting Policies, for further information.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.